Testing two antibody medicines for advanced bladder and other cancers
Part of Cancer clinical trials.
This Phase 2 trial studies whether the study medicines SI-B003 alone or together with BL-B01D1 plus SI-B003 can shrink or control advanced cancers that have not responded to standard treatment (or where standard treatment isn’t possible). It also looks at safety and how well the treatment works in people whose cancer can be measured on scans.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old, and can reasonably be expected to live at least 3 months
- Your cancer is advanced or has spread (metastatic), and has been confirmed by pathology or cytology
- You have tried standard treatments before (or couldn’t tolerate or access them), and you have measurable disease on scans
- You are well enough to do daily activities (ECOG 0–1) and side effects from prior treatment are mostly back to mild levels
- Your blood, kidney, liver, and clotting test results meet the study limits, and your heart function is adequate
- You can provide tumor tissue from the last 3 years (or the doctor can approve enrollment without it)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests BL-B01D1 to treat people with advanced or metastatic urothelial (urinary tract) cancer and other solid tumors. You may be eligible if standard treatments are no longer working or are not available, and you can meet safety and cancer-measurement requirements.
This trial tests a new experimental drug combination (BL-B01D1 with a PD-1 immunotherapy) for advanced bladder cancer that has not yet been treated with whole-body therapy. The goal is to see if this combination can shrink tumors and help people live longer without their cancer getting worse.
This trial tests a new drug called BL-B01D1 against standard chemotherapy for people with advanced bladder cancer that has stopped responding to platinum chemo and immunotherapy. The goal is to see if the new drug works better.
This Phase 1/2 study tests BL-B01D1 in people with recurrent or metastatic gynecologic cancers (such as ovarian, uterine, or cervical cancer) when standard treatments have failed or aren’t options. It focuses on how well the drug works and whether it can be given safely.
This trial tests a new medicine, PF-08046876, for people with advanced cancers of the bladder, lung, head and neck, esophagus, or pancreas. It aims to see if the drug is safe and works against these cancers.
This trial tests a new combination of two drugs—9MW2821 (an antibody-drug conjugate) and Toripalimab (an immunotherapy)—given before and after surgery for muscle-invasive or high-risk urothelial cancer that has not spread. The goal is to see if this combined treatment can improve outcomes.
Hear when a new Urothelial Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.